文献速递骨质疏松与代谢性骨病

硝苯地平临床使用与骨质疏松风险的相关性:一项全国性回顾性队列研究

Association between clinical use of nifedipine and the risk of osteoporosis: a nationwide retrospective cohort study.
PubMed 文献 · Osteoporos Int · 2023-04-20

本研究利用台湾全民健康保险研究数据库2000至2013年数据,纳入接受硝苯地平治疗的1225例患者与接受其他钙通道阻滞剂的4900例患者进行回顾性队列分析。结果显示硝苯地平组骨质疏松风险低于其他钙通道阻滞剂组(校正HR 0.44,95%CI 0.37-0.53),两性和各年龄组均可见此负相关。作者认为硝苯地平可能对骨质疏松具有潜在保护作用,但其临床意义需进一步研究。

要点

  • 硝苯地平组骨质疏松风险低于其他CCB组,校正HR 0.44(95%CI 0.37-0.53)。
  • 该负相关在两性和各年龄组中均可见。
  • 作者认为硝苯地平可能对骨质疏松有潜在保护作用,临床意义需进一步研究。

核心结论

  • 基于人群的队列研究显示,与其他CCB相比,硝苯地平可能对骨质疏松具有潜在保护作用。
  • 作者指出本研究的临床意义需进一步研究。

研究设计与样本

  • 回顾性队列研究,使用台湾全民健康保险研究数据库2000至2013年数据。
  • 暴露队列为接受硝苯地平治疗的1225例患者,对照队列为接受其他CCB治疗的4900例患者。
  • 主要结局为骨质疏松的诊断,采用风险比(HR)及95%置信区间(CI)评估关联。

主要发现

  • 接受硝苯地平治疗的患者较接受其他CCB治疗者骨质疏松风险降低(校正HR 0.44;95%CI 0.37-0.53)。
  • 该负相关在两性和各年龄组中均可见。

关键数值与推荐

  • 硝苯地平组与其他CCB组比较:校正HR 0.44(95%CI 0.37-0.53)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Nifedipine is one of the common calcium channel blockers (CCBs) for hypertension that induce peroxisome-proliferator-activated receptor γ coactivator 1-α, which is envisioned as a potential therapeutic target in bone disease. The findings of this retrospective cohort study suggest that patients who receive nifedipine may have a potential protective effect on osteoporosis in comparison to other CCBs. INTRODUCTION: Nifedipine was one L-type dihydropyridine calcium channel blocker (CCB) that can improve bone loss. However, epidemiological studies on the association between the use of nifedipine and osteoporosis risk are limited. Thus, this study aimed to evaluate the association between the clinical use of nifedipine and the risk of osteoporosis. METHODS: This retrospective cohort was conducted using the National Health Insurance Research Database of Taiwan from 2000 to 2013. The study includes 1225 patients receiving nifedipine (the exposed cohort) and 4900 patients receiving other CCBs (the comparison cohort). The primary outcome was the diagnosis of osteoporosis. The hazard ratios (HRs) and 95% confidence intervals (CIs) were used to assess the association between the use of nifedipine and the risk of osteoporosis. RESULTS: Patients receiving nifedipine treatment had a reduced risk of osteoporosis as compared with those undergoing other CCB treatments (adjusted HR, 0.44; 95% CI, 0.37-0.53). Moreover, this inverse association is evident in both sexes and various age groups. CONCLUSIONS: This population-based cohort study demonstrated that nifedipine may have potential protective effect on osteoporosis compared with other CCBs. The clinical implications of the present study need further investigation.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Chang CM, Chen YC, Wu WT, et al. Association between clinical use of nifedipine and the risk of osteoporosis: a nationwide retrospective cohort study. Osteoporos Int. 2023. PMID: 37079024. doi:10.1007/s00198-023-06756-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。